Novel Therapies for Thyroid Autoimmune Diseases

References

• Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis. BMJ. 2014;349:g5128.
   PubMed Web of Science ®Google Scholar
• Pedersen IB, Laurberg P, Knudsen N, et al. An increased incidence of overthypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J Clin Endocrinol Metab. 2007;92:3122–3127.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Rossi RT, Bonaffini O, et al. Increased annual frequency of Hashimoto’s thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. Ann Endocrinol (Paris). 2010;71:525–534.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174–180.
   PubMed Web of Science ®Google Scholar
• Ma J, Wu D, Li C, et al. Lower serum 25-hydroxyvitamin D level is associated with 3 types of autoimmune thyroid diseases. Medicine (Baltimore). 2015;94:e1639.
   Google Scholar
• Tognini S, Pasqualetti G, Calsolaro V, et al. Cognitive function and quality of life in mild thyroid hormone deficiency. Recent Pat Endocr Metab Immune Drug Discov. 2014;8:124–134.
   PubMedGoogle Scholar
• Wiersinga WM. Quality of life in Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:359–370.
   PubMed Web of Science ®Google Scholar
• Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–738.
   PubMed Web of Science ®Google Scholar
• Smith TJ. Pathogenesis of Graves’ orbitopathy: a 2010 update. J Endocrinol Invest. 2010;33:414–421.
   PubMed Web of Science ®Google Scholar
• Minich WB, Dehina N, Welsink T, et al. Autoantibodies to the IGF1 receptor in Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98:752–760.
   PubMed Web of Science ®Google Scholar
• Wall JR, Lahooti H, El Kochairi I, et al. Thyroid-stimulating immunoglobulins as measured in a reporter bioassay are not detected in patients with Hashimoto’s thyroiditis and ophthalmopathy or isolated upper eyelid retraction. Clin Ophthalmol. 2014;8:2071–2076.
   PubMedGoogle Scholar
• Lahooti H, Parmar KR, Wall JR. Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role? Clin Ophthalmol. 2010;4:417–425.
   PubMedGoogle Scholar
• Brix TH, Hegedüs L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf). 2012;76:457–464.
   PubMed Web of Science ®Google Scholar
• Laurberg P, Jørgensen T, Perrild H, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol. 2006;155:219–228.
   PubMed Web of Science ®Google Scholar
• Carlé A, Bülow Pedersen I, Knudsen N, et al. Smoking cessation is followed by a sharp but transient rise in the incidence of overt autoimmune hypothyroidism - a population-based case-control study. Clin Endocrinol (Oxf). 2012;77:764–772.
   PubMed Web of Science ®Google Scholar
• Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol (Oxf). 2013;78:155–164.
   PubMed Web of Science ®Google Scholar
• Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J. 2009;6:5.
   PubMed Web of Science ®Google Scholar
• Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010–2017.
   PubMed Web of Science ®Google Scholar
• Indolfi G, Stagi S, Bartolini E, et al. Thyroid function and anti- thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf). 2008;68:117–121.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16:563–572.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism. 2008;57:1270–1277.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine. 2008;42:137–143.
   PubMed Web of Science ®Google Scholar
• Blackard JT, Kong L, Huber AK, et al. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid. 2013;23:863–870.
   PubMed Web of Science ®Google Scholar
• Menconi F, Hasham A, Tomer Y. Environmental triggers of thyroiditis: hepatitis C and interferon-α. J Endocrinol Invest. 2011;34:78–84.
   PubMed Web of Science ®Google Scholar
• Simmonds MJ. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat Rev Endocrinol. 2013;9:277–287.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Coperchini F, Magri F, et al. Serum-negative autoimmune thyroiditis: what’s in a name? J Endocrinol Invest. 2014;37:589–591.
   PubMed Web of Science ®Google Scholar
• Lahooti H, Cultrone D, Edirimanne S, et al. Novel single-nucleotide polymorphisms in the calsequestrin-1 gene are associated with Graves’ ophthalmopathy and Hashimoto’s thyroiditis. Clin Ophthalmol. 2015;9:1731–1740.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Falorni A, De Bellis A, et al. Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab. 2005;90:2357–2363.
   PubMed Web of Science ®Google Scholar
• Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab. 2003;88:2983–2992.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fazzi P, Fallahi P, et al. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest. 2006;130:526–532.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Mosca M, et al. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. Metabolism. 2010;59:896–900.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol. 2007;156:431–437.
   PubMed Web of Science ®Google Scholar
• Alfaris N, Curiel R, Tabbara S, et al. Autoimmune thyroid disease and Sjögren syndrome. J Clin Rheumatol. 2010;16:146–147.
   PubMed Web of Science ®Google Scholar
• Namjou B, Kelly JA, Kilpatrick J, et al. Linkage at 5q14.3-15 in multiplex systemic lupus erythematosus pedigrees stratified by autoimmune thyroid disease. Arthritis Rheum. 2005;52:3646–3650.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol. 2002;20:693–696.
   PubMed Web of Science ®Google Scholar
• Fiore E, Rago T, Latrofa F, et al. Hashimoto’s thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer. 2011;18:429–437.
   PubMed Web of Science ®Google Scholar
• Boi F, Minerba L, Lai ML, et al. Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest. 2013;36:313–320.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev. 2014;13:272–280.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med. 2008;25:1349–1353.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr Relat Cancer. 2009;16:1299–1311.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Frascerra S, et al. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine. 2011;55:288–293.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Chiovato L, Romagnani S, et al. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28:492–520.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Chiovato L. The chemokine system as a therapeutic target in autoimmune thyroid diseases: a focus on the interferon-γ inducible chemokines and their receptor. Curr Pharm Des. 2011;17:3202–3216.
   PubMed Web of Science ®Google Scholar
• Kimura H, Kimura M, Rose NR, et al. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto’s thyroiditis. Exp Mol Pathol. 2004;77:161–167.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Ferrari SM, et al. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves’ ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2006;91:614–620.
   PubMed Web of Science ®Google Scholar
• Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89:207–215.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves’ disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab. 2009;94:1803–1809.
   PubMed Web of Science ®Google Scholar
• Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev. 2010;10:116–122.
   PubMed Web of Science ®Google Scholar
• Romagnani P, Rotondi M, Lazzeri E, et al. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves’ disease. Am J Pathol. 2002;161:195–206.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Fallahi P, et al. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf). 2006;64:189–195.
   PubMed Web of Science ®Google Scholar
• Inukai Y, Momobayashi A, Sugawara N, et al. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves’ disease. Eur J Endocrinol. 2007;156:623–630.
   PubMed Web of Science ®Google Scholar
• Brück P, Bartsch W, Sadet D, et al. A CXC motif ligand 10 polymorphism as a marker to predict severity of Graves’ disease. Thyroid. 2010;20:343–345.
   PubMed Web of Science ®Google Scholar
• Sakai H, Togawa Y, Fukuda G, et al. Serum chemokine (C-X-C motif) ligand 10 levels are elevated in patients with Graves’ disease in long-term remission. Thyroid. 2010;20:341–342.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Rotondi M, et al. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves’ disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg. 2006;93:1226–1231.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Rotondi M, Fallahi P, et al. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves’ disease or toxic nodular goiter. J Clin Endocrinol Metab. 2007;92:1485–1490.
   PubMed Web of Science ®Google Scholar
• Leite AC, Pedro AB, Romaldini JH. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves’ disease. Horm Metab Res. 2011;43:194–199.
   PubMed Web of Science ®Google Scholar
• Fuentes E, Guzmán-Jofre L, Moore-Carrasco R, et al. Role of PPARs in inflammatory processes associated with metabolic syndrome (Review). Mol Med Rep. 2013;8:1611–1616.
   PubMed Web of Science ®Google Scholar
• Schaefer KL, Denevich S, Ma C, et al. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis. 2005;11:244–252.
   PubMed Web of Science ®Google Scholar
• Lee JW, Bajwa PJ, Carson MJ, et al. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10 deficient mice. Gastroenterology. 2007;133:108–123.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Frascerra S, et al. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves’ disease. Exp Cell Res. 2011;317:1527–1533.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Frascerra S, et al. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves’ and normal thyrocytes. J Clin Endocrinol Metab. 2010;95:E413–E420.
   PubMed Web of Science ®Google Scholar
• Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048–32054.
   PubMed Web of Science ®Google Scholar
• Crescioli C, Cosmi L, Borgogni E, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol. 2007;195:145–155.
   PubMed Web of Science ®Google Scholar
• Yellin M, Paliienko I, Balanescu A, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:1730–1739.
   PubMed Web of Science ®Google Scholar
• Mayer L, Sandborn WJ, Stepanov Y, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014;63:442–450.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97:4454–4463.
   PubMed Web of Science ®Google Scholar
• Ahuja A, Anderson SM, Khalil A, et al. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A. 2008;105:4802–4807.
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581.
   PubMed Web of Science ®Google Scholar
• Descotes J. Immunotoxicity of monoclonal antibodies. MAbs. 2009;1:104–111.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Public Health Advisory: life-threa-tening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment. 2006. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124345.htm
   Google Scholar
• Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008;8:144–146.
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Curro` N, et al. A small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012;130:122–124.
   PubMedGoogle Scholar
• Mitchell AL, Gan EH, Morris M, et al. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves’ orbitopathy. Clin Endocrinol (Oxf). 2013;79:437–442.
   PubMed Web of Science ®Google Scholar
• Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100:432–441.
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–431.
   PubMed Web of Science ®Google Scholar
• Emerson CH. When will thyrotropin receptor antagonists and inverse thyrotropin receptor agonists become available for clinical use? Thyroid. 2011;21:817–819.
   PubMed Web of Science ®Google Scholar
• Turcu AF, Kumar S, Neumann S, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab. 2013;98:2153–2159.
   PubMed Web of Science ®Google Scholar
• Salvi M. Immunotherapy for Graves’ ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014;21:409–414.
   PubMed Web of Science ®Google Scholar
• Smith TJ. Is IGF-I receptor a target for autoantibody generation in Graves’disease? J Clin Endocrinol Metab. 2013;98:515–518.
   PubMed Web of Science ®Google Scholar
• Chen H, Mester T, Raychaudhuri N, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014;99:E1635–E1640.
   PubMed Web of Science ®Google Scholar
• Chen H, Shan SJ, Mester T, et al. TSH-mediated TNFα production in human fibrocytes is inhibited by teprotumumab, an IGF-1R antagonist. PLoS One. 2015;10:e0130322.
   Google Scholar
• Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74:1379–1410.
   PubMed Web of Science ®Google Scholar
• Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond). 2005;19:1286–1289.
   PubMed Web of Science ®Google Scholar
• Salvi M, Girasole G, Pedrazzoni M, et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves’ disease. J Clin Endocrinol Metab. 1996;81:2976–2979.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–1523.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006.
   PubMed Web of Science ®Google Scholar
• Pérez-Moreiras JV, Alvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant graves’ orbitopathy. Ophthal Plast Reconstr Surg. 2014;30:162–167.
   PubMed Web of Science ®Google Scholar
• Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2000;85:776–780.
   PubMed Web of Science ®Google Scholar
• Hiromatsu Y, Fukazawa H, Wall JR. Cytotoxic mechanisms in autoimmune thyroid disorders and thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am. 1987;16:269–286.
   PubMed Web of Science ®Google Scholar
• Mysliwiec J, Palyga I, Kosciuszko M, et al. Circulating CXCL9 and CXCL10 as markers of activity of Graves’ orbitopathy during treatment with corticosteroids and teleradiotherapy. Horm Metab Res. 2012;44:957–961.
   PubMed Web of Science ®Google Scholar
• Zhu W, Ye L, Shen L, et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2014;99:1999–2007.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism. 2011;60:277–283.
   PubMed Web of Science ®Google Scholar